Epstein-Barr virus-induced proteins. IV. Characterization of an EBV-associated phosphopolypeptide.
Cells of the Epstein--Barr virus (EBV) non-producing lines NC37 and Raji were induced by the tumour promoter TPA and were labelled with 32P. The analysis by immunoprecipitation with human VCA+EA+ sera revealed that a major phosphopolypeptide with a mol. wt. of 58 000 was specifically precipitated. In addition, a phosphopolypeptide of the same size was the dominant phosphopolypeptide detected in EBV-producing B95-8 and P3HR-1 cells as well as in P3HR-1-superinfected NC37 cells. This phosphopolypeptide seemed to be EBV-specific, because it was not detectable in TPA-treated, but EBV genome-negative, Ramos and BJAB cells. Synthesis of this phosphopolypeptide was inhibited in TPA-treated NC37 cells by treatment with Ara-C. VCA+EA+ sera were found to be more immunoreactive with this phosphopolypeptide than VCA+EA- or EBNA+ sera. Based on these results this phosphopolypeptide may have some immunological relatedness to the EBV-specific early antigen (EA) complex defined by immunofluorescence.
D000956:Antigens, Viral / Q000032:analysis; D002460:Cell Line; D003561:Cytarabine / Q000494:pharmacology; D004854:Herpesvirus 4, Human / Q000032:analysis* / Q000378:metabolism; D006801:Humans; D008970:Molecular Weight; D010748:Phosphopeptides / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D010766:Phosphorylation; D014764:Viral Proteins / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology
D000956:Antigens, Viral; D010748:Phosphopeptides; D014764:Viral Proteins; D003561:Cytarabine